Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1 daily bars · split adjusted
Current price $26.31
Latest analyst grade actions
Stock news · updated daily
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the pricing of its upsized initial public offering of 17,640,000 shares of its common stock at an initial public offering price of $18.00 per share.
Drug developer Lycia Therapeutics targets $938 million valuation in US IPO
Reported EPS vs. consensus estimate
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | LYCA | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | — | — · sector 20.7x | n/a |
| Forward P/E | — | — | n/a |
| Price / Book | — | — | n/a |
| Price / Sales | — | — | n/a |
| EV / EBITDA | — | — | n/a |
| Return on equity | — | — | n/a |
| Gross margin | — | — | n/a |
| Debt / Equity | — | — | n/a |
| Piotroski / Altman Z | —/9 | Z — | n/a |
Discounted cash flow model